Grant Private Wealth Management Inc Invests $457,000 in Thermo Fisher Scientific Inc. $TMO

Grant Private Wealth Management Inc acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 943 shares of the medical research company’s stock, valued at approximately $457,000.

Other institutional investors have also bought and sold shares of the company. Brighton Jones LLC boosted its position in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares during the period. Watts Gwilliam & Co. LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter valued at approximately $218,000. Wellington Management Group LLP raised its position in shares of Thermo Fisher Scientific by 11.7% during the first quarter. Wellington Management Group LLP now owns 1,595,715 shares of the medical research company’s stock worth $794,028,000 after purchasing an additional 167,763 shares during the period. Finally, Texas Capital Bank Wealth Management Services Inc lifted its holdings in shares of Thermo Fisher Scientific by 181.6% in the 1st quarter. Texas Capital Bank Wealth Management Services Inc now owns 2,267 shares of the medical research company’s stock worth $1,128,000 after purchasing an additional 1,462 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a research note on Sunday, December 7th. Barclays raised their price target on shares of Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Wells Fargo & Company increased their price objective on Thermo Fisher Scientific from $635.00 to $675.00 and gave the stock an “overweight” rating in a research note on Monday. The Goldman Sachs Group started coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 target price on the stock. Finally, Morgan Stanley increased their price target on Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $616.60.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $64,400,668.20. This represents a 5.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Frederick M. Lowery sold 6,912 shares of the stock in a transaction on Tuesday, December 2nd. The shares were sold at an average price of $581.94, for a total value of $4,022,369.28. Following the transaction, the executive vice president directly owned 14,367 shares of the company’s stock, valued at approximately $8,360,731.98. This trade represents a 32.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 149,271 shares of company stock worth $86,507,282 in the last three months. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Down 1.0%

TMO stock opened at $570.07 on Wednesday. The stock has a market cap of $214.18 billion, a P/E ratio of 32.93, a P/E/G ratio of 4.21 and a beta of 0.90. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The stock’s fifty day simple moving average is $567.10 and its two-hundred day simple moving average is $494.60. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. The company had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $5.28 EPS. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has approved a share buyback plan on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback plans are generally a sign that the company’s management believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.